Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

Abbott completes acquisition of Exact Sciences

AI-generated analysis

🏥 Abbott has officially completed its acquisition of Exact Sciences to become a leader in cancer screening and diagnostics.

📅 The transaction closed on March 20, 2026, with that date marking the last day of trading for Exact Sciences shares on Nasdaq.

📑 Upon completion, Exact Sciences became a wholly owned subsidiary of Abbott under the terms of their merger agreement.

💼 This deal establishes leadership in the fast-growing U.S. cancer screening and precision oncology diagnostics segments valued at $60 billion.

🚀 The acquisition adds new growth to Abbott's portfolio, reinforcing its high-single-digit growth expectations for the business unit.

🧬 Abbott now offers a comprehensive suite including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard® for early detection.

👨‍⚕️ Robert B. Ford, Abbott's CEO, stated that the company's global scale will expand access to tools for early cancer detection.

🌍 The deal supports Abbott's mission to advance preventative, predictive, and personalized diagnostics as global cancer incidence rises.

🧪 Next-generation products have been added to the pipeline to detect cancer earlier and optimize treatment decisions.

⚠️ Abbott disclosed forward-looking statements regarding risks related to integration operations and realizing anticipated synergies.

📄 Interested parties can review detailed risk factors in Abbott's and Exact Sciences' 10-K filings from December 31, 2025.

🌐 Abbott continues its broader mission with 122,000 colleagues serving people in over 160 countries across various healthcare segments.

Bullish Signals
  • Abbott has completed the acquisition of Exact Sciences, establishing itself as a leader in the fast-growing cancer screening and diagnostics segments.
  • The transaction adds a new growth vertical to Abbott's portfolio, expanding its presence in the approximately $60 billion U.S. cancer screening and precision oncology diagnostics market.
  • Abbott now offers a comprehensive suite of products including the Cologuard® test, Oncotype DX®, Oncodetect®, and Cancerguard®, enhancing early detection capabilities.
  • Robert B. Ford, CEO, stated that Abbott's global scale and operational excellence will expand access to tools for early cancer detection and personalized treatments.
  • The acquisition enables Abbott to serve millions of additional people, reinforcing its mission to make healthcare more accessible.
  • Abbott now possesses a leading pipeline of next-generation screening technologies designed to detect cancer earlier and enable regular monitoring to help patients manage the disease.
Risk Factors
  • The acquisition introduces substantial integration risks, including the potential for Abbott to fail in successfully integrating Exact Sciences' operations.
  • There is a significant risk that anticipated synergies and benefits from the transaction may not be realized or will take longer than expected to materialize.
  • Abbott must successfully implement its plans and forecasts regarding Exact Sciences' business post-transaction, which carries uncertainty.
  • Readers are cautioned against relying on forward-looking statements regarding the acquisition's success, as Abbott undertakes no obligation to release revisions to these statements.
Full Analysis
Abbott Laboratories (NYSE: ABT) announced on March 23, 2026, that it has completed its acquisition of Exact Sciences. Following the completion of the deal, Exact Sciences became a wholly owned subsidiary of Abbott, and trading for Exact Sciences shares ceased on Nasdaq with March 20, 2026, being the final trading day. Robert B. Ford, Abbott's CEO, stated that the company's global scale and operational excellence will expand access to early cancer detection tools and personalized treatments, leveraging Exact Sciences' deep expertise. The transaction positions Abbott as a leader in fast-growing cancer screening and diagnostics segments, specifically within the $60 billion U.S. cancer screening and precision oncology diagnostics market. Abbott now offers a comprehensive suite of products for early cancer detection and treatment support, including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard®. Additionally, Abbott has acquired a pipeline of next-generation cancer screening technologies designed to detect cancer earlier, optimize treatment decisions, and enable regular monitoring for disease management. The acquisition is expected to serve millions of additional people and establish leadership in one of healthcare's fastest-growing areas as global cancer incidence rises. This adds a new growth vertical to Abbott, which already has high-single-digit growth expectations. The press release concludes with standard forward-looking statements regarding integration risks, synergy realization, and uncertainties related to future operations and financial performance. Note: While the provided text contains some unrelated boilerplate content in German regarding energy markets and a different ticker (ABB/BL), the core news story focuses entirely on Abbott's completion of the Exact Sciences acquisition, making this article valuable for investors seeking information on this major transaction.